• 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • br Conclusions br In this study


    5. Conclusions
    In this study, we constructed the human prostate cancer PC-3-luc Mitoquinol with a stable expression of the luciferase gene and it was have the same biological characteristics as PC-3 cells, so PC-3-luc cells can replace PC-3 cells for in vivo and in vitro experiments. Ad-VT has the characteris-tics of tumor-specific replication and specific tumor killing, and through a variety of in vitro and in vivo experiments, it was confirmed that Ad-VT has a significant inhibitory 
    effect on PC-3 cells, indicating that Ad-VT has potential clinical development value to treat prostate cancer.
    Author contributions
    Ningyi Jin and Xiao Li coordinated the study and pro-vided funding. Weihua Wang coordinated the study too. Chuanxin Cui designed and performed the experiments and analyzed the data. Yujia Sun, Yilong Zhu, Jinbo Fang, Bing Bai, Wenjie Li, Shanzhi Li and Yizhen Ma assisting per-formed the experiment, Chuanxin Cui wrote the manuscript with substantial contribution, Yiquan Li participated in editing the manuscript. All authors reviewed the results and approved the final version of the manuscript.
    Conflicts of interest statement
    The research was conducted in the absence of any com-mercial or financial relationships that could be construed as a potential conflict of interest.
    Informed consent
    Informed consent was obtained from all individual par-ticipants included in the study.
    Ethical approval
    All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
    This work was supported by the National Key Research and Development Program of China [grant number 2016YFC1200900], the National Science and Technology Major Project (Major New Drugs Innovation and Develop-ment) [grant number 2018ZX09301053-004-001], Key Tech-nologies R&D Program of Jilin Province [20160209015YY], and the Major Technological Program of Changchun City [grant number 16ss11].
    [1] Kovac JR, Pan MM, Lipshultz LI, Lamb DJ. Current state of practice regarding testosterone supplementation therapy in men with prostate cancer. Steroids 2014;89:27–32.
    [4] Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002;2:103–23.
    [6] Gokce MI, Wang X, Frost J, Roberson P, Volk RJ, Brooks D, et al. Informed decision making before prostate-specific antigen screening: initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer 2017;123:583–91.
    [8] Bell JC, McFadden G. Editorial overview: oncolytic viruses−repli-cating virus therapeutics for the treatment of cancer. Curr Opin Virol 2015;13:viii-ix.
    [13] Deng WP, Yang WK, Lai WF, Liu RS, Hwang JJ, Yang DM, et al. Non-invasive in vivo imaging with radiolabelled FIAU for monitor-ing cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir. Eur J Nucl Med Mol Imaging 2004;31: 99–109.
    [16] Zhao H, Doyle TC, Coquoz O, Kalish F, Rice BW, Contag CH. Emis-sion spectra of bioluminescent reporters and interaction with mamma-lian tissue determine the sensitivity of detection in vivo. J Biomed Opt 2005;10:41210.
    [17] Fraga H, Fernandes D, Novotny J, Fontes R, Esteves da Silva JC. Firefly luciferase produces hydrogen peroxide as a coproduct in dehy-droluciferyl adenylate formation. Chembiochem 2006;7:92935.
    [19] Noteborn MH, de Boer GF, van Roozelaar DJ, Karreman C, Kranen-burg O, Vos JG, et al. Characterization of cloned chicken anemia virus DNA that contains all elements for the infectious replication cycle. J Virol 1991;65:3131–9.